SecBot SecBot
PRESS-RELEASE ·Filed Apr 8, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming clinical milestones: readout from the CLBP Phase 3 trial later this year, initiation of the DMD registrational trial, and site activation in the adult SR-aGvHD study. The CAR technology acquisition could enhance product potency and create long-term value, but near-term revenue will be driven by Ryoncil® adoption.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.92
T+0 close · Apr 8, 2026 · via day close
Latest settled
+3.30%
T+60 · $14.38
Vs SPY
−7.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $13.92entry
  2. T+1 · 7mo ago +4.53%α +3.95% · $14.55
  3. T+5 · 7mo ago +13.15%α +9.63% · $15.75
  4. T+20 · 7mo ago +13.43%α +4.89% · $15.79
  5. T+60 · 4mo ago +3.30%α −7.15% · $14.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close of enrollment in its Phase 3 trial for chronic low back pain (CLBP), received FDA clearance for a registrational trial in pediatric Duchenne muscular dystrophy (DMD), and acquired a patented CAR technology platform from Mayo Clinic to enhance its MSC therapies. The updates were shared during its R&D Day webcast.

Key Financial Metrics

Revenue
$100.0M

Key Facts

  • Ryoncil® is approaching $100 million in net revenue since its launch last year.
  • Enrollment in the Phase 3 trial for chronic low back pain (CLBP) is closing at the end of the month.
  • FDA cleared an IND to proceed directly to a registrational trial for Ryoncil® in pediatric DMD.
  • Central IRB approval obtained for adult SR-aGvHD trial; first sites to activate this quarter.
  • Acquired a patented CAR technology platform from Mayo Clinic to enhance MSC-based therapies.

Financial Impact

Ryoncil® nearing $100M in net revenue indicates growing commercial traction; DMD and CLBP programs represent significant future revenue potential.

revenuepipeline valueR&D expense

Risk Factors

  • Clinical trial setbacks in CLBP, DMD, or SR-aGvHD could delay approvals.
  • Regulatory delays or rejections despite IND clearance.
  • Forward-looking statements carry uncertainty; actual results may differ materially.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3270209

Track record

25 reports on MESO

Performance horizon

6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026